The global PD1 Resistant Head and Neck Cancer Market size is expected to be worth US$ 1.54 billion in 2023, rising to US$ 5 billion by 2033, with a CAGR of 12.5%. The growing geriatric population, as well as initiatives by government and non-governmental organisations like Support for People with Oral and PD1 Resistant Head and Neck Cancer (SPOHNC), are all contributing to this market’s favourable growth environment.
Immunotherapy is a novel cancer treatment strategy that can be used to treat a variety of tumours such as head and neck cancer, lymphoma, melanoma, and non-small cell lung cancer. While traditional chemotherapy works well for some tumours, immunotherapy is often used in conjunction with conventional cancer therapies to increase the body’s natural defences against cancer. The immune system works by recognising and removing aberrant cells, preventing or slowing the development of many cancers. Immune cells can be detected in and around tumours. Alcohol and cigarette use are thought to be responsible for 75% of head and neck malignancies.
Request a Sample of this Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16237
However, normal head and neck cancer treatments frequently include a combination of radiation and chemotherapy, which can result in hair loss, speech difficulties, and the loss of one’s natural voice. Patients who have had cancer surgery may also have problems eating. These elements are expected to limit market expansion.
Key Takeaways
- With a CAGR of 11.1% during the projected period, North America is expected to dominate the Head and Neck cancer market.
- During the projection period, APAC is expected to develop at the quickest CAGR of 11.5%.
- PDL1 Inhibitors is expected to lead the market in terms of product type.
- Advances in biochemistry and genomics, such as immunotherapy, will drive market growth.
- By 2033, North America is expected to dominate the PDL1 segment market.
- China will dominate the APAC market in 2023, with a market value of US$ 250 million.
“With rapid advancements in oncology, healthcare practitioners are discovering novel approaches to diagnose and treat the most debilitating cancers, including PD1 resistant HNC. This is paving way for various avenues for developing treatment approaches,” remarks an FMI analyst.
For any queries linked with the report, ask an analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-16237
Competitive Landscape
Key players in the Head and Neck Cancer market are: Advaxis, Inc, Amgen, Inc., AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cel-Sci Corporation, GlaxoSmithKline plc, Incyte Corporation, Merck KGaA, Novartis AG.
- In February 2020, Galera Therapeutics, Inc., announced that Avasopasem manganese (GC4419), a novel drug molecule is in their pipeline. Avasopasem manganese (GC4419), the candidate drug molecule is being developed for reducing the severe oral mucositis (SOD) which is normally induced due to radiotherapy. Avasopasem manganese (GC4419) selectively and rapidly convert superoxide into hydrogen peroxide and oxygen, which in turn protect the normal tissues from the ill-effects of superoxide. If the condition is left untreated, the superoxide can attack and damage the non-cancerous tissue, leading to many side-effects, which can limit the efficiency of radiotherapy in the patients.
- In July 2022, Bristol Myers Squibb received positive Committee for Medicinal Products for Human Use (CHMP) opinion recommending approval for LAG-3-blocking antibody combination Opdualag (nivolumab and relatlimab) for the treatment of patients with unresectable or metastatic melanoma.
- In October 2021, Merck received the United States Food and Drug Administration (FDA) approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1, as determined by an FDA-approved test.
Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16237
Key Segments Profiled in the PD1 Resistant Head and Neck Cancer Market Industry Survey
PD1 Resistant Head and Neck Cancer Market by Product:
Cytotoxic Agents
- Antimetabolites
- Antitubulins
- Others – Platinum Agents, Fluoropyrimidines
EGFR Inhibitors
- Erbitux
- Vectibix
- Theracim/Theraloc
EGFR Inhibitors
- Tarceva
- Tykerb/Tyverb
PD1 Inhibitors
- Keytruda
- Opdivo
Pipeline Drugs
- EGFR Inhibitors
- PDL1 Inhibitors
- CTLA4 Inhibitors
About Future Market Insights, Inc.
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn | Twitter | Blogs
